Business Wire

Immunocore Appoints Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer

Share

Immunocore Limited, a leading T cell receptor (TCR) biotechnology company, today announces that Dr Mohammed Dar has been appointed as Head of Clinical Development and Chief Medical Officer, effective April 16, 2019.

Commenting on the appointment, Bahija Jallal Chief Executive Officer of Immunocore, said: “Immunocore is approaching a crucial point in the Company’s development, with our lead product candidate, tebentafusp, moving through pivotal studies. Mohammed has a complete breadth of experience in leading clinical teams through early and late stage development. We’re delighted to have such a distinguished physician, scientist and industry leader join us as we progress tebentafusp and our other promising candidates through clinical development.

Mohammed will be responsible for clinical, operational, biostatistics and medical affairs functions across all therapeutic areas. This includes Immunocore’s wholly-owned lead programme, tebentafusp, in addition to the growing pipeline in oncology, infectious diseases, which includes target indications such as Hepatitis B and HIV, and autoimmune diseases.

“The potential of Immunocore’s unparalleled science and TCR platform is very impressive,” said Mohammed Dar, Head of Clinical Development and Chief Medical Officer of Immunocore. “I am thrilled to have joined Immunocore at such an exciting time for the Company and I look forward to working with the scientific leadership team to drive this compelling science forward.”

Mohammed has over 15 years of pharmaceutical industry experience in the field of oncology. Before joining Immunocore, Mohammed was Vice President, Clinical Development Oncology, R&D at MedImmune (AstraZeneca) and spent 10 years at GSK in roles of increasing responsibility focused on early clinical development in oncology. While at MedImmune, he led the clinical trials and teams supporting the approval of anti-PD-L1 checkpoint inhibitor, durvalumab, and anti-CD22 immunotoxin, moxetumomab. Mohammed received his Bachelor’s Degree in Chemistry from the University of North Carolina at Chapel Hill and his M.D. and Internal Medicine training from Duke University School of Medicine. He went on to complete his Fellowship in Hematology and Oncology at the National Cancer Institute.

Mohammed joins two other world-class development leaders at Immunocore, Mark Moyer, Head of Regulatory, Safety and Project Management, and Koustubh Ranade, Head of Translational Medicine. Mark is one of the most experienced immuno-oncology development leaders with over 30 years of drug development experience at companies including Bristol-Myers Squibb (BMS) and Sanofi. As regulatory oncology head at BMS, he was accountable for 37 BLAs/MAAs, including for nivolumab, ipilimumab and elotuzumab. Koustubh was most recently Vice President of Translational Medicine at MedImmune for all therapeutic areas, where he contributed to four product approvals, including durvalumab. With over three decades of research experience at Genentech, BMS, Stanford and NIH, Koustubh is a co-inventor on many patents, has published extensively in top-tier journals and has edited a book on genomics.

About Immunocore

Immunocore, a leading T Cell Receptor (TCR) biotechnology company, is focused on delivering first-in-class

biological therapies that have the potential to transform the lives of people with serious diseases. The Company’s primary therapeutic focus is oncology and it also has programmes in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programmes in development and the lead programme, tebentafusp (IMCgp100), has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with offices in Conshohocken and Rockville, USA. The Company is privately held by a broad international investor base. For more information, please visit www.immunocore.com.

Contact information

Immunocore
Louise Conlon, External Affairs and Brand Communications Manager
T: +44 (0) 1235 438600
E: info@immunocore.com
Follow on Twitter: @Immunocore

Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/Jessica Hodgson/Chris Welsh/Melissa Gardiner
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Assimoco Group Selects Moody’s Analytics SolvencyWatch ™ Solution29.5.2020 11:00:00 CESTPress release

Moody’s Analytics, a global provider of financial intelligence, today announced that its software has been selected by Assimoco Group, an Italian insurance group and the insurance provider for the Italian Cooperative Movement since 1978. Assimoco Group will use the Moody’s Analytics SolvencyWatch solution to monitor key solvency metrics. Powered by Moody’s Analytics award-winning modeling capabilities, the SolvencyWatch solution quickly calculates an insurer’s assets and liabilities to reflect the latest market conditions, enabling chief risk officers (CROs) to monitor their solvency position in real time. The tool’s intuitive dashboard allows CROs and risk teams to visualize the impact on crucial solvency metrics under changes to market and non-market risks, and communicate to stakeholders what is driving changes in those metrics. “The Moody’s Analytics SolvencyWatch solution will allow us to monitor our solvency position frequently, accurately, and cost effectively,” said Ruggero Fre

Wipro Appoints Thierry Delaporte as CEO & Managing Director29.5.2020 07:21:00 CESTPress release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the appointment of Thierry Delaporte as the Chief Executive Officer and Managing Director of the company, effective July 6, 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005916/en/ Thierry Delaporte (Photo: Business Wire) Until recently, Thierry Delaporte was the Chief Operating Officer of Capgemini Group and a member of its Group Executive Board. During his twenty-five year career with Capgemini, he held several leadership roles including that of Chief Executive Officer of the Global Financial Services Strategic Business Unit, and head of all global service lines. He also oversaw Capgemini’s India operations, and led the group’s transformation agenda, conceptualizing and driving several strategic programs across various business units. “I am delighted to

Ipsen Appoints David Loew as Chief Executive Officer29.5.2020 07:05:00 CESTPress release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005876/en/ David Loew, CEO at Ipsen as of July 1st 2020 (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its Board of Directors has appointed David Loew as its new Chief Executive Officer (CEO) and as Board member. The CEO appointment will take effect on July 1st, 2020. The Board of Directors expresses its gratitude to Aymeric Le Chatelier, who steered the group very well in an exceptionally challenging environment and who will remain in the role of acting CEO until July 1st, 2020 and will continue in his role of Chief Financial Officer. David Loew will be based at Ipsen’s headquarters in Boulogne-Billancourt, France. His mission will be to ensure Ipsen’s continued growth and to advance its pipeline via a long-term value-adding external innovation strategy, while fostering a culture of entrepreneurship, agility and patient-cent

New data show first-line triplet regimen of pembrolizumab, Herzuma ® (biosimilar trastuzumab) and chemotherapy are effective in treatment of HER2-positive advanced gastric cancer29.5.2020 01:01:00 CESTPress release

Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma®(biosimilar trastuzumab) and chemotherapy is effective in patients with HER2-positive advanced gastric cancer (AGC). The PANTHERA trial (a phase Ib/II study of first line pembrolizumab in combination with trastuzumab, capecitabine, and cisplatin in HER2-positive gastric cancer), sponsored by Celltrion Inc. and MSD, is investigating the potential of a first-line immunotherapy/chemotherapy combination with biosimilar trastuzumab. This is in light of a growing body of evidence that the immune system contributes to the therapeutic effects of monoclonal antibodies such as biosimilar trastuzumab in treating solid tumours.1 A total of 43 patients were treated with a median follow up of 18 months. Patients were treated with pembrolizumab 200mg via IV infusion D1,biosimilar trastuzumab 6mg/kg (after 8mg/kg load) D1, capecitabine 1000mg/m2 bid D1-D14 a

European Commission Releases Takeda From Commitment to Divest Shire’s Pipeline Compound SHP64729.5.2020 01:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announces that on May 28, the European Commission (the “EC”) has released Takeda from the obligation to divest the pipeline compound SHP647 and certain associated rights (“SHP647”), a commitment that was provided by Takeda to secure regulatory clearance of its acquisition of Shire plc (“Shire”). Takeda will discontinue the current SHP647 clinical trial program, and it will be providing all eligible trial participants with the opportunity to have continued access to SHP647 in a post-trial access (“PTA”) study. In addition, subject to obtaining trial participant consents and the satisfaction of regulatory and ethical considerations, Takeda will make SHP647 clinical trial data and biosamples available to the scientific community through the Crohn’s & Colitis Foundation (“Foundation”). Takeda announced on November 20, 2018, that the EC approved its proposed acquisition of Shire (the “Acquisition”). The EC’s appr

Jefferies' Clients, Employees and Shareholders Contribute $9,250,000 to Over 85 Charities for Coronavirus Relief in Memory of Peg Broadbent28.5.2020 18:02:00 CESTPress release

Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease. Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000. “We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charit